| Literature DB >> 29392565 |
Naomi Sanda1,2, Nobuaki Suzuki3, Atsuo Suzuki1, Takeshi Kanematsu4, Mayuko Kishimoto4, Hidetoshi Hasuwa5,6, Akira Takagi7, Tetsuhito Kojima7, Tadashi Matsushita8,4, Shigeo Nakamura2.
Abstract
Von Willebrand factor (VWF) is synthesized in megakaryocytes and endothelial cells (ECs) and has two main roles: to carry and protect coagulation factor VIII (FVIII) from degradation by forming VWF-FVIII complex; and to mediate platelet adhesion and aggregation at sites of vascular injury. Previous research using the HEK293 cell line revealed that the VWF K1362 mutation interacted directly with platelet glycoprotein Ib (GPIb). Vwf K1362A knock-in (KI) mice were therefore generated to verify the in vivo function of residue 1362 in binding to platelet GPIb. The Cre-loxP system was employed to introduce the Vwf K1362A mutation systemically in mice. In blood coagulation analysis, the VWF antigen (VWF:Ag) of Lys1362Ala KI homozygous (homo) mice was below the sensitivity of detection by enzyme-linked immunosorbent assay. FVIII activities (FVIII:C) were 47.9 ± 0.3 and 3.3 ± 0.3% (K1362A heterozygous (hetero) and K1362A KI homo mice, respectively) compared to wild-type mice. Immunohistochemical staining analysis revealed that VWF protein did not exist in ECs of K1362A KI homo mice. These results indicated that VWF protein synthesis of K1362A was impaired after transcription in mice. K1362 seems to represent a very important position not only for VWF function, but also for VWF synthesis in mice.Entities:
Keywords: Genetic mutation; Mouse model; Von Willebrand factor
Mesh:
Substances:
Year: 2018 PMID: 29392565 DOI: 10.1007/s12185-017-2394-y
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490